The p53 tumor suppressor: Critical regulator of life & death in cancer

Apoptosis

Volumn 6, Issue 1-2, 2001, Pages 7-15

  Fisher, D E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Caspase; P53; Tumor suppressor

Indexed keywords

PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; FAMILIAL CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS;

ANIMALIA;

EID: 0035082454     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009659708549     Document Type: Review

References (113)

1. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse
2. T antigen is bound to a host protein in SV40-transformed cells
3. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
4. Suppression of human colorectal carcinoma cell growth by wild-type p53
5. Genetic mechanisms of tumor suppression by the human p53 gene
6. Wildtype p53 can inhibit oncogene-mediated focus formation
7. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53
8. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
9. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
10. Tumor spectrum analysis in p53-mutant mice
11. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene
12. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
13. p53 mutations in human cancers
14. Mutations in the p53 gene occur in diverse human turnout types
15. Participation of p53 protein in the cellular response to DNA damage
16. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia
17. Wildtype p53 is a cell cycle checkpoint determinant following irradiation
18. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
19. p53 status and the efficacy of cancer therapy in vivo
20. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
21. Apoptosis in cancer therapy: Crossing the threshold
22. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression
23. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription
24. p53 binds to the TATA-binding protein-TATA complex
25. Wild-type p53 binds to the TATA-binding protein and represses transcription
26. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein
27. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60
28. Human TAFII31 protein is a transcriptional coactivator of the p53 protein
29. Recruitment of p300/CBP in p53-dependent signal pathways
30. Identification of a novel p53 functional domain that is necessary for efficient growth suppression
31. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression
32. Allosteric activation of latent p53 tetramers
33. Specific sequences from the carboxyl terminus of human p53 gene product from anti-parallel tetramers in solution
34. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding
35. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms
36. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
37. Signaling to p53: Breaking the MDM2-p53 circuit
38. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
39. A novel protein with strong homology to the tumor suppressor p53
40. p73 is a simian [correction of human] p53-related protein that can induce apoptosis
41. A second p53-related protein, p73L, with high homology to p73
42. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
43. Two new p73 splice variants, gamma and delta, with different transcriptional activity
44. p63 is a p53 homologue required for limb and epidermal morphogenesis
45. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
46. Regulation of proliferation-survival decisions during tumor cell hypoxia
47. The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53
48. Participation of the human p53 3'UTR in translational repression and activation following gammairradiation
49. Translational regulation of human p53 gene expression
50. Transciptional regulation of the p53 tumor suppressor gene
51. Regulation of p53 stability by Mdm2
52. Keeping an old friend under control: Regulation of p53 stability
53. New HPV E6 binding proteins: Dangerous liaisons?
54. The mdm-2 gene is induced in response to UV light in a p53-dependent manner
55. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
56. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
57. Regulation of p53 function and stability by phosphorylation
58. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
59. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
60. p300/MDM2 complexes participate in MDM2-mediated p53 degradation
61. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
62. Mdm2 binds p73 alpha without targeting degradation
63. MDM2 suppresses p73 function without promoting p73 degradation
64. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53
65. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
66. Enhanced phosphorylation of p53 by ATM in response to DNA damage
67. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
68. ATM associates with and phosphorylates p53: Mapping the region of interaction
69. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53
70. DNA damage induced p53 stabilization: No indication for an involvement of p53 phosphorylation
71. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
72. Cell cycle. Piecing together the p53 puzzle
73. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
74. Cell cycle arrest and DNA endoreduplication following p21 Waf1/Cip1 expression
75. E1A signaling to p53 involves the p19(ARF) tumor suppressor
76. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
77. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
78. p53 is required for radiation-induced apoptosis in mouse thymocytes
79. Thymocyte apoptosis induced by p53-dependent and independent pathways
80. Loss of arm radiosensitizes multiple p53 null tissues
81. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo
82. WAF1, a potential mediator of p53 tumor suppression
83. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
84. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
85. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
86. Radiation-induced cell cycle arrest compromised by p21 deficiency
87. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
88. DNA damage-inducible transcripts in mammalian cells
89. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
90. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin
91. Induction of the growth inhibitor IGF-binding protein 3 by p53
92. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
93. Bax-deficient mice with lymphoid hyperplasia and male germ cell death
94. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
95. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
96. On the TRAIL from p53 to apoptosis?
97. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo
98. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
99. A model for p53-induced apoptosis
100. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
101. Induction of apoptosis in HeLa cells by trans-activation-deficient p53
102. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway
103. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
104. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types
105. Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system
106. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
107. Bcl-2 blocks p53-dependent apoptosis
108. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest
109. Clinical implications of the p53 tumor-suppressor gene
110. p53 and cancer therapy: A double-edged sword
111. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells
112. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
113. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors